Dr. Kaundinya is an industry visionary in the development and application of novel technologies for characterization and engineering complex biomolecules. At Momenta, Dr. Kaundinya leads the application of the technology to enable generic versions of marketed complex biological products as well as applications for discovery and development of novel drugs for unmet disease areas. Dr. Kaundinya developed and implemented the science that led to the recent FDA approval of the leading product, M-Enoxaparin™, a generic version of Sanofi-Aventis’ heparin drug Lovenox. M-Enoxaparin™ was the first interchangeable generic low molecular weight heparin approved in the United States as an ANDA. He also leads the research and development of the novel drug portfolio at Momenta. Dr. Kaundinya has authored more than 60 publications and over 30 patents and patent applications. Prior to founding Momenta, Dr. Kaundinya was a member of the MIT research faculty where he pioneered research in the area of characterization and biology of complex carbohydrates. Dr. Kaundinya earned both his M.S. and Ph.D. in Chemical Engineering from Massachusetts Institute of Technology.